The cost-effectiveness of mirtazapine versus paroxetine in treating people with depression in primary care

International Clinical Psychopharmacology

Volumn 19, Issue 3, 2004, Pages 125-134

  Romeo, Renee ^a   Patel, Anita ^a   Knapp, Martin ^a,b   Thomas, Christine ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Antidepressants; Cost effectiveness; Costs; Depression; Mirtazapine; Paroxetine; Primary care

Indexed keywords

MIRTAZAPINE; PAROXETINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEPRESSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUBLIC HEALTH SERVICE; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; UNITED KINGDOM;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; COST-BENEFIT ANALYSIS; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIANSERIN; MIDDLE AGED; PAROXETINE; PRIMARY HEALTH CARE; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 2342580135     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200405000-00002     Document Type: Article

References (29)

1. Berndt ER, Finkelstein SN, Greenberg PE, Howland RH, Keith A, Rush AJ, et al. (1998). Workplace performance effects from chronic depression and its treatment. J Health Econ 17:511-535.
2. Bower P, Byford S, Sibbald B, Wasrd E, King M, Lloyd M, Gabby M (2000). Randomised controlled trial of non-directive counselling, cognitive-behaviour therapy, and usual general practitioner care for patients with depression II: Cost-effectiveness. BMJ 321:1389-1392.
3. Briggs AH (2000). Economic evaluation and clinical trials: size matters. BMJ 321:1362-1383.
4. Briggs AH (2001). A Bayesian approach to stochastic cost-effectiveness analysis. Int J Technol Assess Health Care 17:69-82.
5. Briggs AH, Wonderling DE, Mooney CZ (1997). Pulling cost-effectiveness analysis up by it bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 6:327-340.
6. British National Formulary 44 (2002). British Medical Association and Royal Pharmaceutical Society of Great Britain. September London: BMA, RPS.
7. Byford S, Harrington R, Torgerson D, Kerfoot M, Dyer E, Harrington V et al. (1999). Cost-effectiveness analysis of home-based social work intervention for children and adolescents who have deliberately poisoned themselves. Br J Psychiatry 176:56-62.
8. Department of Health (2002). National Health Service Schedule of Reference Costs 2002. http://www.doh.gov.uk/nhsexec/refcosts.htm [accessed December 2002].
9. Depression Alliance 2002. Depression: Facts and Statistics. http://www.depressionalliance.org [accessed December 2002].
10. Drummond M, O'Brien B, Stoddart GL, Torrance GW (1997). Methods for the Economic Evaluation of Health Care Programs, 2nd ed. Oxford: Oxford Medical Publications.
11. Ellis BW, Johns MW, Lancaster R, Raptopulos P, Angelopoulos N, Priest RG (1981). The St Mary's Hospital sleep questionnaire: a study of reliability. Sleep 4:93-97.
12. Finn W, Hyslop J, Truman C (2000). Mental Health, Multiple Needs and the Police. Findings From the Revolving Doors Agency Link Worker Scheme. London: Revolving Doors Agency.
13. Green B (1997). The treatment of depression. Psychiatry On-Line. http:// www.priory.com/treatment.htm [accessed December 2002].
14. Guy W (1976). ECDU Assessment Manual for Psychopharmacology, rev. edn. US Department of Health, Education and Welfare. Publication No. (ADM) 76-338. Rockville, MD: National Institute of Mental Health. pp. 218-222.
15. Hamilton M (1960). Rating scales in depression. J Neurol Neurosurg Psychiatry 23:56-62.
16. Hunt SM, McKenna SP (1992). The OLDS: a scale for the measurement of quality of life in depression. Health Policy 22:307-319.
17. Jenkins J (2001). Patterns of Pay: Results of the 2001 New Earnings Survey. London: Employment and Productivity Division, Office of National Statistics.
18. Kind P, Sorensen J (1993). The cost of depression. Int Clin Psychopharmacol 7:191-195.
19. Koopmanschap MA, van Ineveld BM (1992). Towards a new approach for estimating indirect costs of disease. Soc Sci Med 34:105-1010.
20. Lecrubier Y (2001). The burden of depression and anxiety in general medicine. J Clin Psychiatry 62 (suppl 8):4-9.
21. Lepine JP, Gastpar M, Mendlewicz J, Tylee A (1997). Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). Int Clin Psychopharmacol 12:19-29.
22. Netten A, Curtis L (2002). Unit Costs of Health and Social Care. Canterbury: PSSRU, University of Kent.
23. Perez-Stable EJ, Miranda J, Munoz RF, Ying Y-W (1990). Depression in medical outpatients. Under recognition and misdiagnosis. Arch Gen Med 150:1083-1088.
24. Simon G, Ormel J, VonKorff M, Barlow W (1995). Health care costs associated with depressive and anxiety disorders in primary care. Am J Psychiatry 3:352-357.
25. Thase ME (2000). Relapse and recurrence in depression: an updated practical approach for prevention. In: Palmer KJ (editor): Drug Treatment Issues in Depression. Auckland, New Zealand: Adis International Ltd. pp. 35-52.
26. Thase ME (2001). Methodology to measure onset of action. J Clin Psychiatry 61 (suppl 15):18-22.
27. Thomas C, Morris S (2003). The cost of depression among adults in England in 2000. Br J Psychiatry 183:514-519.
28. UK 700 case management trial (2000). Cost-effectiveness of intensive versus standard case management for severe psychotic illness. Br Jr Psychiatry 176:537-543.
29. Wade A, Crawford GM, Angus M, Wilson R, Hamilton L (2003). A randomized, double-blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care. Int Clin Psychopharmacol 18:133-141.